Pan-cancer analysis of CD2AP revealed that its protein levels were evaluated in most types of cancers (Figure 4C), except for clear cell renal cell carcinoma (CCRCC), head and neck squamous cell carcinomas (HNSCC), and lung squamous cell carcinoma (LSCC). Here, CD2AP is linked to clear cell renal carcinoma.